Arvinas reports Q4/FY2024 results; VERITAC-2 Phase 3 topline data expected in Q1 2025

ARVINAS, INC.

2024-FY EPS reported -$2.77 revenue$263,400,000

Cash, cash equivalents and marketable securities $1,039.4M as of Dec 31, 2024; revenue $263.4M.
VERITAC-2 Phase 3 monotherapy topline data in ER+/HER2- mBC anticipated in 1Q25; two new Phase 3 combos planned in 2025.
ARV-102 (LRRK2 degrader) Phase 1 in Parkinson's initiated; SAD data in healthy volunteers to be presented at AD/PD in April 2025.
Alex Santini appointed interim Chief Commercial Officer effective January 17, 2025.
Cash runway sufficient into 2027; VERITAC-3 (vepdegestrant+palbociclib) discontinued beyond study lead-in.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.